Vaxart Inc

NASDAQ:VXRTUnited States

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Contact Information

Headquarters

170 Harbor Way, Suite 300SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-550-3500

Fax

650-871-8580

Executives

Chairman of the Board, Interim Chief Executive Officer

Michael Finney

President, Chief Executive Officer, Director

Steven Lo

Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

Phillip Lee

Senior Vice President, Chief Scientific Officer

Sean Tucker

Senior Vice President, General Counsel

Edward Berg